Unexplored therapeutic opportunities in the human genome

Nature Reviews Drug Discovery 17, 377 (2018). doi:10.1038/nrd.2018.52 Author: Tudor I. Oprea, Cristian G. Bologa, Søren Brunak, Allen Campbell, Gregory N. Gan, Anna Gaulton, Shawn M. Gomez, Rajarshi Guha, Anne Hersey, Jayme Holmes, Ajit Jadhav, Lars Juhl Jensen, Gary L. Johnson, Anneli Karlson, Andrew R. Leach, Avi Ma'ayan, Anna Malovannaya, Subramani Mani, Steven L. Mathias, Michael T. McManus, Terrence F. Meehan, Christian von Mering, Daniel Muthas, Dac-Trung Nguyen, John P. Overington, George Papadatos, Jun Qin, Christian Reich, Bryan L. Roth, Stephan C. Schürer, Anton Simeonov, Larry A. Sklar, Noel Southall, Susumu Tomita, Ilinca Tudose, Oleg Ursu, Dušica Vidovic´, Anna Waller, David Westergaard, Jeremy J. Yang & Gergely Zahoránszky-Köhalmi Nature Reviews Drug Discovery (2018); 10.1038/nrd.2018.14In the version of this article that was originally published online, an older version of the data set categorizing proteins into target development levels was used to create Figure 1 than the version used to create
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: Corrigendum Source Type: research